172 related articles for article (PubMed ID: 21093020)
21. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
Fernández-Espartero MC; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
Semin Arthritis Rheum; 2011 Feb; 40(4):330-7. PubMed ID: 20864146
[TBL] [Abstract][Full Text] [Related]
22. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry.
Pérez-Sola MJ; Torre-Cisneros J; Pérez-Zafrilla B; Carmona L; Descalzo MA; Gómez-Reino JJ;
Med Clin (Barc); 2011 Nov; 137(12):533-40. PubMed ID: 21514606
[TBL] [Abstract][Full Text] [Related]
23. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists.
García-Doval I; Pérez-Zafrilla B; Descalzo MA; Roselló R; Hernández MV; Gómez-Reino JJ; Carmona L;
Ann Rheum Dis; 2010 Oct; 69(10):1751-5. PubMed ID: 20551153
[TBL] [Abstract][Full Text] [Related]
24. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
25. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population.
Abásolo L; Júdez E; Descalzo MA; González-Alvaro I; Jover JA; Carmona L;
Semin Arthritis Rheum; 2008 Jun; 37(6):388-97. PubMed ID: 17977580
[TBL] [Abstract][Full Text] [Related]
26. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
27. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
Wolfe F; Michaud K
Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
[TBL] [Abstract][Full Text] [Related]
28. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
[TBL] [Abstract][Full Text] [Related]
29. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience.
Peña-Sagredo JL; Hernández MV; Fernandez-Llanio N; Giménez-Ubeda E; Muñoz-Fernandez S; Ortiz A; Gonzalez-Gay MA; Fariñas MC;
Clin Exp Rheumatol; 2008; 26(5):854-9. PubMed ID: 19032819
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
[TBL] [Abstract][Full Text] [Related]
31. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Nilsson JA; Petersson IF; Lindqvist E; Saxne T; Geborek P
Ann Rheum Dis; 2007 May; 66(5):670-5. PubMed ID: 17158824
[TBL] [Abstract][Full Text] [Related]
32. Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0.
Ventura-Ríos L; Bañuelos-Ramírez D; Hernández-Quiroz Mdel C; Robles-San Román M; Irazoque-Palazuelos F; Goycochea-Robles MV
Reumatol Clin; 2012; 8(4):189-94. PubMed ID: 22673388
[TBL] [Abstract][Full Text] [Related]
33. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
Chakravarty EF; Michaud K; Wolfe F
J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
[TBL] [Abstract][Full Text] [Related]
34. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
[TBL] [Abstract][Full Text] [Related]
35. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
37. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
38. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
[TBL] [Abstract][Full Text] [Related]
39. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.
Cobo-Ibáñez T; Descalzo MÁ; Loza-Santamaría E; Carmona L; Muñoz-Fernández S
Rheumatol Int; 2014 Jul; 34(7):953-61. PubMed ID: 24414744
[TBL] [Abstract][Full Text] [Related]
40. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven RF; Klareskog L
Ann Rheum Dis; 2007 Oct; 66(10):1339-44. PubMed ID: 17261532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
